News for Revolution Medicines, Inc. (RVMD)

**media[552061]**

”“ TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer ”“ ”“ Investigational New Drug (IND) application for TNG456, a next-generation

Revolution Medicines Inc (RVMD) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $0.35 million, and the ear

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ( RVMD), a late-stage clinical oncology company developing novel targeted t

Buying stocks that sell for 100 times revenue or more means facing terrible odds. Of 84 such stocks covered in this column, 60 have declined within a year.

Significant Stock Acquisition by Paradigm Biocapital Advisors LP (Trades, Portfolio) On December 31, 2024, Paradigm Biocapital Advisors LP (Trades, Portfolio) e

On December 31, 2024, Paradigm Biocapital Advisors LP (Trades, Portfolio) executed a significant transaction by acquiring an additional 907,412 shares of Janux

On December 31, 2024, Woodline Partners LP (Trades, Portfolio) executed a significant reduction in its holdings of Travere Therapeutics Inc (TVTX). The firm red

On December 31, 2024, Casdin Capital, LLC (Trades, Portfolio), a prominent investment firm, expanded its holdings in Neurogene Inc by acquiring an additional 27

On December 31, 2024, Janus Henderson Group PLC executed a significant transaction by acquiring 3,346,755 shares of Revolution Medicines Inc at a trade price of

On February 5, 2025, Paradigm Biocapital Advisors LP (Trades, Portfolio) made a significant move by acquiring an additional 950,162 shares of Cogent Biosciences

The mean of analysts' price targets for Revolution Medicines (RVMD) points to a 74.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

**media[527607]**

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on RVMD stock.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Revolution Medicines, Inc.

The heavy selling pressure might have exhausted for Revolution Medicines (RVMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.

Revolution Medicines (RVMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Revolution Medicines Inc (RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, announced that its CEO, Dr